Determinants of mortality and long-term outcome in children with refractory and super refractory status epilepticus

Sita Jayalakshmi1, Anuja Patil1, Anusha Challa1

  • 1Department of Neurology, Krishna Institute of Medical Sciences, Secunderabad, India.

Insights

Progression to super refractory status epilepticus (SRSE) in children with refractory status epilepticus (RSE) did not increase mortality but was linked to poorer outcomes. Over 60% of children experienced good long-term recovery.

Area of Science:

  • Pediatric Neurology
  • Critical Care Medicine
  • Epileptology

Background:

  • Refractory status epilepticus (RSE) is a neurological emergency in children.
  • Progression to super refractory status epilepticus (SRSE) represents a more severe form of RSE.
  • Understanding factors influencing progression and outcomes is crucial for clinical management.

Purpose of the Study:

  • To identify factors associated with the progression of convulsive RSE to SRSE in children.
  • To evaluate the long-term outcomes of children with RSE and SRSE.

Main Methods:

  • Retrospective analysis of data from children admitted with convulsive RSE between 2010 and 2018.
  • Outcome assessment at two years using the Glasgow Outcome Scale (GOS).

Main Results:

  • Of 56 children, 24 progressed to SRSE. Acute symptomatic etiology was common in both RSE and SRSE groups.
  • Children progressing to SRSE had a significantly longer NICU stay (25.2 vs. 4.8 days).
  • Progression to SRSE was associated with poorer GOS outcomes (63.6% vs. 29.4%), but mortality rates were similar between RSE and SRSE groups.

Conclusions:

  • Acute symptomatic etiology is frequent in pediatric RSE and SRSE.
  • Progression to SRSE in children is linked to worse long-term neurological outcomes, not increased mortality.
  • A majority of children (60.7%) achieved a good outcome at follow-up.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
347
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
508
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
656
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
11
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
17